Inspired by PROTACs, new degraders are emerging that harness endocytosis and autophagy to send a wide array of targets to the lysosome for destruction.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
24 November 2022
In the version of this article initially published, the financing listed for PAQ Therapeutics in Table 1, now showing $34 million, appeared initially as $134 million. The table and a summary of spending at the end of the first section have now been updated.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. The lysosomal degraders. Nat Biotechnol 40, 1709–1713 (2022). https://doi.org/10.1038/s41587-022-01594-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01594-7
